Apixaban Cost-effective vs Warfarin in AF: ARISTOTLE Apixaban Cost-effective vs Warfarin in AF: ARISTOTLE

A lifetime on the newer agent was cost-effective within US"reasonable norms" but didn ' t cut overall costs much by improving outcomes, mostly because apixaban itself is far costlier than warfarin.
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news